Vice Director Huang Guo of the National Medical Products Administration Conducted Research on New Mechanism and New Target Drug Development in Beijing

MetaMuskRat · 2026-03-21T02:02:00+00:00

Deputy Director Huang Guo of the National Medical Products Administration conducted research on new drug development, emphasizing the promotion of innovative drug development and review reform, supporting early-stage research and development as well as communication services for major projects, improving service quality, and better meeting the public's medication needs.

MetaMuskRat

2026-03-21 02:02:00

Abstract generation in progress

People’s Financial News, March 19 — On March 19, Huang Guo, member of the Party Leadership Group and Deputy Director of the National Medical Products Administration, led a team to the Beijing Institute of Life Sciences to investigate the development of new mechanisms and new target drug research. A symposium was held to listen to expert opinions and suggestions. The meeting pointed out that the current development trend of innovative drugs in China continues to improve, with a solid foundation and potential for steady quality enhancement, upgrading, and high-level breakthroughs. The NMPA will further focus on original innovation, continue to deepen the reform of review and approval systems, and support “breakthroughs from 0 to 1.” A tracking mechanism for major innovative projects will be established, along with a sound communication and consultation service system for early-stage research and development. Strengthening regulatory science research and application in related fields will improve the service quality and efficiency for major innovative projects, better meeting the public’s medication needs.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes